Abstract

Prion diseases are neurodegenerative disorders characterized by the accumulation of misfolded prion protein, spongiform changes in the brain, and brain inflammation as a result of the wide-spread activation of microglia. Autophagy is a highly conserved catabolic process for the clearance of cytoplasmic components, including protein aggregates and damaged organelles; this process also eliminates pathological PrPSc as it accumulates during prion infection. The NALP3 inflammasome is a multiprotein complex that is a component of the innate immune system and is responsible for the release of pro-inflammatory cytokines. Our previous study showed that the neurotoxic prion peptide PrP106-126 induces NALP3 inflammasome activation and subsequent IL-1β release in microglia. Autophagy is involved in the regulation of the immune responses and inflammation in many diseases including neurodegenerative diseases. However, the relationship between autophagy and NALP3 inflammasome in prion diseases has not been investigated. In this study, we demonstrated that the processing and release of mature IL-1β is significantly enhanced by the inhibition of autophagy. Conversely, gene-silencing of the NALP3 inflammasome promotes autophagy. Suppression of TRIF or TLR4 by siRNA attenuated PrP106-126-induced autophagy, which is indicating that the TLR4-TRIF signaling pathway is involved in PrP106-26-induced autophagy. Caspase 1 directly cleaved TRIF to diminish TLR-4-TRIF mediated autophagy. Our findings suggest that the inhibition of autophagy by NALP3 inflammasome is probably mediated by activated Caspase-1-induced TRIF cleavage. This is the first study reporting that the NALP3 inflammasome complex negatively regulates autophagy in response to PrP106-126 stimulation in microglia, and partly explains the mechanism of autophagy inhibition by Caspase-1 in PrP106-126-induced BV2 cell activation. Our findings suggest that autophagy up-regulation and inhibition of Caspase-1 may protect against prion-induced neuroinflammation and accelerate misfolded protein degradation and are potential therapeutic approaches for prion diseases.

Highlights

  • Prion diseases, known as transmissible spongiform encephalopathies (TSEs), are a family of fatal progressive neurodegenerative disorders that affect humans and several species of animals

  • We examined whether PrP-106-126 induces NALP3 inflammasome activation

  • The expression of inflammasome proteins, NALP3 and ASC were significantly increased in the peptide-treated BV2 cells pre-incubated with the autophagy inhibitor 3-MA, compared with cells treated with PrP106-126 alone (Figures 1E,F)

Read more

Summary

Introduction

Known as transmissible spongiform encephalopathies (TSEs), are a family of fatal progressive neurodegenerative disorders that affect humans and several species of animals. They are characterized by extensive spongiform degeneration, widespread neuronal loss, synaptic alterations, atypical brain inflammation, and microgliosis (Soto and Satani, 2011). PrPSc is protease-resistant, and has a higher proportion of β-sheet structure in place of the normal α-helix structure (Prusiner, 1998; La et al, 2008). The synthetic neurotoxic prion fragment (PrP106-126) possesses similar physicochemical and pathogenic properties to PrPSc, in that it forms amyloid fibrils with a high β-sheet content, shows partial proteinase K resistance, and is toxic to neuronal cells in vitro. PrP106-126 is commonly used as a model for the investigation of PrPSc neurotoxicity (Forloni et al, 1993; Selvaggini et al, 1993; Ettaiche et al, 2000; Gu et al, 2002)

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.